PURPOSE OF REVIEW: Recent breakthroughs in HIV-prevention science led us to evaluate the current state of combination HIV prevention for injection drug users (IDUs). We review the recent literature focusing on possible reasons why coverage of prevention interventions for HIV, hepatitis C virus (HCV) and tuberculosis among IDUs remains dismal. We make recommendations for future HIV research and policy. RECENT FINDINGS: IDUs disproportionately under-utilize voluntary HIV counseling and testing (VCT), primary care and antiretroviral therapy (ART), especially in countries that have the largest burden of HIV among IDUs. IDUs present later in the course of HIV infection and experience greater morbidity and mortality. Why are IDUs under-represented in HIV-prevention research, access to treatment for both HIV and addiction, and access to HIV combination prevention? Possible explanations include addictophobia, apathy, and inattention, which we describe in the context of recent literature and events. SUMMARY: This commentary discusses the current state of HIV-prevention interventions for IDUs including VCT, needle and syringe program (NSP), opioid substitution therapy (OST), ART and pre-exposure chemoprophylaxis (PrEP), and discusses ways to work towards true combination HIV prevention for IDU populations. Communities need to overcome tacit assumptions that IDUs can navigate through systems that are maintained as separate silos, and begin to take a rights-based approach to HIV prevention to ensure that IDUs have equitable access to life-saving prevention and treatments.
PURPOSE OF REVIEW: Recent breakthroughs in HIV-prevention science led us to evaluate the current state of combination HIV prevention for injection drug users (IDUs). We review the recent literature focusing on possible reasons why coverage of prevention interventions for HIV, hepatitis C virus (HCV) and tuberculosis among IDUs remains dismal. We make recommendations for future HIV research and policy. RECENT FINDINGS: IDUs disproportionately under-utilize voluntary HIV counseling and testing (VCT), primary care and antiretroviral therapy (ART), especially in countries that have the largest burden of HIV among IDUs. IDUs present later in the course of HIV infection and experience greater morbidity and mortality. Why are IDUs under-represented in HIV-prevention research, access to treatment for both HIV and addiction, and access to HIV combination prevention? Possible explanations include addictophobia, apathy, and inattention, which we describe in the context of recent literature and events. SUMMARY: This commentary discusses the current state of HIV-prevention interventions for IDUs including VCT, needle and syringe program (NSP), opioid substitution therapy (OST), ART and pre-exposure chemoprophylaxis (PrEP), and discusses ways to work towards true combination HIV prevention for IDU populations. Communities need to overcome tacit assumptions that IDUs can navigate through systems that are maintained as separate silos, and begin to take a rights-based approach to HIV prevention to ensure that IDUs have equitable access to life-saving prevention and treatments.
Authors: M-J Milloy; Thomas Kerr; David R Bangsberg; Jane Buxton; Surita Parashar; Silvia Guillemi; Julio Montaner; Evan Wood Journal: AIDS Patient Care STDS Date: 2011-11-22 Impact factor: 5.078
Authors: Susan D Hillis; Lauren Zapata; Cheryl L Robbins; Dmitry M Kissin; Halyna Skipalska; Roman Yorick; Erin Finnerty; Polly A Marchbanks; Denise J Jamieson Journal: AIDS Date: 2012-01-02 Impact factor: 4.177
Authors: Vu Minh Quan; Nguyen Le Minh; Tran Viet Ha; Nguyen Phuong Ngoc; Pham The Vu; David D Celentano; Tran Thi Mo; Vivian F Go Journal: Addiction Date: 2010-11-04 Impact factor: 6.526
Authors: Steffanie A Strathdee; Timothy B Hallett; Natalia Bobrova; Tim Rhodes; Robert Booth; Reychad Abdool; Catherine A Hankins Journal: Lancet Date: 2010-07-24 Impact factor: 79.321
Authors: Susan C Kim; Stephen Becker; Carl Dieffenbach; Blair S Hanewall; Catherine Hankins; Ying-Ru Lo; John W Mellors; Kevin O'Reilly; Lynn Paxton; Jason S Roffenbender; Mitchell Warren; Peter Piot; Mark R Dybul Journal: J Int AIDS Soc Date: 2010-07-12 Impact factor: 5.396
Authors: Cecilia Tomori; Vivian F Go; Le Nhan Tuan; Nguyen Mai Huong; Nguyen Thanh Binh; Carla E Zelaya; David D Celentano; Do Tuan Dat; Vu Minh Quan Journal: Int J Drug Policy Date: 2014-04-28
Authors: Laramie R Smith; Valerie A Earnshaw; Michael M Copenhaver; Chinazo O Cunningham Journal: Drug Alcohol Depend Date: 2016-02-26 Impact factor: 4.492
Authors: Sten H Vermund; José A Tique; Holly M Cassell; Megan E Pask; Philip J Ciampa; Carolyn M Audet Journal: J Acquir Immune Defic Syndr Date: 2013-06-01 Impact factor: 3.731